Ruti Aga and the six-year ban: a fake prescription from a clinic that never existed

The smallest detail in the file turns out to be the heaviest. The prescription was written on an old pad belonging to a clinic; the clinic later confirmed to the Athletics Integrity Unit that it had never issued it. The person who signed it held no medical registration. That person was a family member of Ruti Aga. And the clinic name printed on the form, upon verification, had never existed in any medical registry. Three layers of fabricated paperwork, stacked on a case whose underlying offence was a glucocorticoid anti-inflammatory prohibited only in competition. The final sanction: six years, running from 10 September. The 2026 Tokyo Marathon champion becomes eligible again at 38, if she wants to come back at all. Aga is 32. She won Tokyo in 2026, finished runner-up at World Marathon Majors events three times, and sat inside Ethiopia's distance elite through the 2026–2026 window. For a female marathoner, 32 is peak, not decline; the elite window commonly stretches to 35 or 37. The ban lands precisely at the point of maximum sporting and commercial value. The case began at a half marathon in China in March, which she won. Her sample returned an adverse finding for methylprednisolone. Here I have to stop, because nearly every report I read calls the substance a "steroid," and that is scientifically wrong. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid — not an anabolic-androgenic steroid. Under the WADA list it sits in class S9, prohibited in competition only, and is classified as a Specified Substance, a category the code itself acknowledges is more plausibly linked to therapeutic or inadvertent use. That distinction is not academic trivia. It determines the entire architecture of the sanction, and whether readers understand the case at all. Jurisdictionally, this was never a race organiser's matter. The Athletics Integrity Unit, World Athletics' independent integrity body, handled testing, results management and prosecution under the WADA Code. That is why the ban is global rather than confined to the race where the sample was taken. The six years is an addition, not a single number. Two years is the baseline for presence of a Specified Substance absent proof of intent. Four years is the baseline for tampering with results management. The WADA Code requires independent violations to be served consecutively, not concurrently. Two plus four equals six. The decisive point: the cover-up was punished twice as hard as the substance. The investigating body penalised the concealment at double the rate of the prohibited substance itself. The tampering file is about as airtight as integrity work gets. The clinic named on the form confirmed it had not issued the document. Registration checks found no trace of the signatory. The signatory claimed to have used an old pad from a former employer, and that employer confirmed she had never worked there. Four independent verifications, four identical conclusions. There was no seam for a lawyer to work. The athlete's explanation was a knee injury, treated with medication. That story is entirely plausible. Glucocorticoids are potent anti-inflammatories used routinely in sport for joint inflammation, tendonitis and chronic pain. An intra-articular injection close to competition would produce an in-competition positive with no intent to enhance performance whatsoever. The legitimate route for exactly that scenario has existed for years: a Therapeutic Use Exemption. An athlete with knee inflammation, medical records, a specialist's signature and a TUE filed before use is not in violation. Even a rushed, honest disclosure of a therapeutic error typically yields a materially lighter outcome. The substance side of this case was always the softer half. A Specified Substance in class S9, prohibited in competition only, with a clear therapeutic pathway — everything pointed toward mitigation. Fabricating the prescription destroyed that pathway. A case that could have ended in a warning, or no sanction at all, was converted into six years. I have watched East African distance running long enough to know why this happens. The high-altitude camp system of the Rift Valley produces more marathon champions than any region on earth, and it comes bundled with an almost non-existent legal support structure. Athletes raised in that system learn to run 200 kilometres a week, to read a pace split, to eat before and after a session. They are not taught to read the prohibited list, to file a TUE, or to call a lawyer when an integrity body issues a summons. When I produced the "Invisible Tacticians" report during the shutdown, what struck me was that East African women goalkeepers were hand-drawing tactical notebooks out of cardboard, designing their own defensive systems because no specialist coach existed. Scarcity breeds invention. But one kind of scarcity breeds only disaster: the absence of anyone who knows the rules. A camp with thirty athletes and one manager does not have a person who has read the WADA Code. That is why I read the Aga case as a system failure rather than a sophisticated doping operation. A clinic that does not exist, an old prescription pad, a relative playing doctor — that is the work of people with no integrity expertise around them. Anyone with counsel would never fabricate a document to conceal a substance that is only banned in competition. There is a layer almost nobody mentions. The Chinese road circuit, where the March half marathon took place, is a dense appearance-fee market for East African runners: high race volume, attractive purses, large invited fields, and on-site medical scrutiny far thinner than at the majors. It is the place where mistakes are most likely, and where almost nobody checks medical paperwork before an athlete steps to the line. On the transfer map, women are numbers filed in the wrong column. On the roads, they are the names invited for lower appearance fees, routed into smaller races more often, and frequently travelling without a personal doctor. When things go well, nobody notices. When a sample comes back adverse, that same absence becomes evidence against them. The 2026 World Cup showed me that Nigerians were being looked at, not watched. The same holds on the roads. When a Black East African woman tests positive, the story told is not about a medical error that could happen to anyone, but about a body under suspicion. Same anti-inflammatory, same TUE process, entirely different narration depending on whose name is in the file. And that narration outlives the ban by years. One technical detail in the international coverage bothers me: calling methylprednisolone a "steroid." A general reader sees that word and pictures testosterone, muscle doping, cheating for performance. The reality is an anti-inflammatory any sports clinic in Europe prescribes daily. Misnaming the substance inflates perceived severity and turns a paperwork case into a classic doping case. Those are different things, and the rules treat them differently. I do not go looking for a level playing field. I draw my own lines. If the media names the substance wrongly, the job of a specialist writer is to name it correctly. If the investigating body reached an accurate conclusion, the job is to say clearly which part was accurate. Both at once, or the piece becomes either an indictment or a defence brief. On the AIU's conclusion, I have nothing to defend. A fabricated prescription is a deliberate act. Tampering with results management is an independent violation, and four years is a baseline, not a discretion. An athlete who signs her name to a file containing a forged prescription owns that file. There is no grey area. But responsibility does not stop at the signature. A relative stepping forward as a doctor, using an old pad, inventing a clinic — that person did not think of it alone. Someone in the athlete's circle said this would work. In a system with integrity counsel, the answer to "what do I do about an adverse finding" is already written into process: declare, file the therapeutic record, apply for retroactive TUE where eligible, cooperate with the investigation to earn reduction. I once saw the reverse at a much smaller scale. In 2026, when I published data on the high-pressing model of Kenyan women's football teams, two journalists called it a joke. I did not argue with feeling; I invited them to watch the footage. Data does not need an advocate, only someone willing to sit and look. The Aga file is the same: four layers of verification are public, and they state plainly what happened. The question I would put to the sport is not whether six years is too harsh. It is this: in the past twelve months, how many East African women athletes received proper education on the prohibited list and the TUE process? If the answer is none, Ruti Aga will not be the last case. She will be the first one caught with full documentation. Ethiopia's women's marathon bench is deep enough that removing a major champion barely shifts the competitive balance of the event. The next name is already on the start line of the next race. That depth is the strength of the national system, and simultaneously the reason nobody has to build legal support around any individual. One leaves, ten remain. Nobody is accountable for the fact that the one who left was unprotected. East Africa does not lack women's football talent; it lacks people who write it down. I have said that to colleagues for years, and it holds on the roads too: no shortage of women running under 2:20, only a shortage of people who sit down and read the file with them. The first channel is always the hardest, but somebody has to hold the microphone. And once you hold it, the next job is to point at the part of the system that leaves runners to manage alone. The sanction runs from 10 September. The March half marathon result will almost certainly be annulled along with its prize money. For six years there will be no World Marathon Majors invitation, no appearance fee, no new sponsorship. For a professional marathoner, that is the entire revenue stack. Commercially, the ban ended the career before the competition did. One possibility the coverage rarely raises: her earlier samples may be reviewed, particularly now that a tampering finding exists. Long-term storage and the athlete biological passport are available tools. Even results already ratified are not entirely immune. So what changes? I do not believe in grand commitments. I believe in small, countable things. A mandatory prohibited-list session for every athlete in a training camp. A 24-hour legal contact for every national federation. A TUE form translated into Amharic and Swahili and pinned where everyone can see it. All of that costs far less than a six-year ban. I still watch East African women's racing every weekend, because it teaches me more about human improvisation under scarcity than anything else I cover. But I do not want to see another medal exchanged for a prescription pad. If organisers, federations and management agencies treat this file as a lesson about paperwork rather than morality, it will have done something useful. If they only read the sanction, then in six years a few more names will walk into the same room with the same form, and nobody will be there to tell them another road existed.